Clinical Trial Update: Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

View source ↗

Summary

A post-marketing surveillance study in Japan evaluating the combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) for unresectable hepatocellular carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• IMJUDO (TREMELIMUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Unresectable Hepatocellular Carcinoma | Status: COMPLETED